Fetscher S, Lübbert M, Kanz L, Behringer D, Finke J, Mertelsmann R, Lange W
Division of Hematology and Oncology, Department of Internal Medicine, University of Freiburg Medical Center, Germany.
Bone Marrow Transplant. 1997 Mar;19(5):527-8. doi: 10.1038/sj.bmt.1700690.
We report a patient with centroblastic non-Hodgkin's MALT lymphoma of the stomach treated initially with surgery and post-operative chemotherapy and radiotherapy. First relapse was treated with high-dose BEAM chemotherapy and autologous peripheral blood stem cell transplantation (PBSCT). Second, systemic relapse was treated with high-dose BU/CY and second PBSCT. Today, the patient is in complete remission at 27+ months. The case indicates a curative potential for high-dose BU/CY chemotherapy as salvage therapy for relapsed high-grade lymphoma after BEAM and autologous PBSCT. This may have implications for the prevention as well as for the management of lymphoma relapse after high-dose chemotherapy (HDC) and autologous PBSCT.
我们报告了一名患有胃中心母细胞性非霍奇金黏膜相关淋巴组织淋巴瘤的患者，最初接受了手术及术后化疗和放疗。首次复发时采用大剂量BEAM化疗及自体外周血干细胞移植（PBSCT）进行治疗。第二次系统性复发时采用大剂量BU/CY及第二次PBSCT进行治疗。如今，该患者在27个多月时处于完全缓解状态。该病例表明，大剂量BU/CY化疗作为BEAM和自体PBSCT后复发的高级别淋巴瘤的挽救治疗具有治愈潜力。这可能对大剂量化疗（HDC）和自体PBSCT后淋巴瘤复发的预防及管理具有启示意义。
